The Sole Reason Teva Pharmaceutical Industries Ltd. Sank 12% in November

The Sole Reason Teva Pharmaceutical Industries Ltd. Sank 12% in November


The lone reason for the drop appears to be its less-than-stellar third-quarter earnings report and outlook. On Nov. 15, Teva announced revenue of $5.6 billion, a 19% increase from the prior-year quarter on a constant-currency basis, while non-GAAP operating income grew by 16% to $1.8 billion.



from Biotech News